The prospect of receiving anti-retroviral therapy was brought a little closer to millions of HIV-positive Kenyans recently, with the announcement of a price reduction for some of the drugs that are used to treat AIDS. British-based pharmaceutical giant GlaxoSmithKline (GSK) said last week that it would cut the price of various anti-retrovirals (ARV’s) from between 25 to 43 percent. This comes amidst an ongoing campaign by AIDS activists to lower the cost of ARV’s, which prolong the lives of people infected with the human immunodeficiency virus.